A Phase 2 interventional study of Alpha 1-Antitrypsin in Graft-versus-host-disease and GVHD, sponsored by John Levine. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-12.
Sponsored by John Levine · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.
Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 192nd largest by enrollment of the 389 interventional ones that give a count, is one of 15 that started in 2018, is one of 164 in phase 2, and was the 343rd registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 7+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Regenerative Ocular Immunobiologics LLC · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Sawa Ito, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 145 · Phase 2 227 · Phase 3 48 · Phase 4 5
First in 1986; this study’s year is marked. 15 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 30 across the 389 interventional studies, 81 across the 43 observational. Of the 347 that completed or were terminated, 166 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 454 have an industry lead sponsor. The 10 most frequent:
John Levine is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
John Levine has 5 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Graft vs Host Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07776210Phase 3Regenerative Ocular Immunobiologics LLCStudy of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD) | 2027-03-31 |
| NCT06649201Case Comprehensive Cancer CenterVulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation | 2026-11 |
| NCT05675930Memorial Sloan Kettering Cancer CenterA Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | 2026-12-22 |
| NCT04044365National Cancer Institute (NCI)Pediatric cGVHD Symptom Scale | 2026-12-31 |
| NCT03533816University of Kansas Medical CenterExpanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | 2027-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 454 studies in Graft vs Host Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bone marrow transplant (BMT) patients can develop graft-versus-host disease (GVHD), a serious and potentially fatal complication. The researchers have developed a blood test to identify patients most at risk for developing severe GVHD. Patients who consent to this study will have their blood tested up to two times after BMT to determine if they are at high risk for severe GVHD. The tests will be performed one week and two weeks after BMT. Patients who are high risk will be treated with a drug called alpha-1-antitrypsin (AAT) to see if it prevents the development of severe GVHD. Patients will receive 16 doses of AAT through a catheter placed into a blood vessel over eight weeks. AAT will be given either in the hospital or the outpatient clinic two times per week. Patients will be followed for the development of severe GVHD for up to four months from the BMT and will continue to be followed at routine clinic visits for up to one year after BMT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
Drug: Alpha 1-Antitrypsin
AAT will be given either in the hospital or the outpatient clinic two times per week.
Also known as: AAT
Number of High Risk Patients Who Develop Steroid Refractory GVHD
Number of High Risk patients who develop steroid refractory GVHD by day 100 post Hematopoietic cell transplant (HCT) . Steroid refractory GVHD defined as patients who did not achieve Complete Response (CR) or Partial Response (PR) by day 28 of systemic steroid treatment OR if additional immunosuppression beyond steroids was given for treatment of GVHD prior to 28 days of steroid treatment. * CR: All evaluable organs (skin, liver, GI tract) stage 0. For a response to be scored as CR on day 28, the patient must be in CR on that day and have had no intervening additional GVHD therapy. * PR: An improvement in one or more organ involved with GVHD symptoms without worsening in others. For a response to be scored as PR on day 28, the patient must be in PR on that day and have had no intervening additional GVHD therapy.
Time frame: Day 100 post HCT.
Number of Participants Alive at 6 Months and 1 Year
Overall survival - The number of that patients are still alive from the start of treatment at 6 months and 1 year
Time frame: 6 months and 1 year
Number of Participants With Non-relapse Mortality (NRM)
Number of participants with NRM - deaths which could not be attributed to disease relapse or progression. Non-relapse mortality defined as death without prior relapse.
Time frame: 6 months and 1 year
Number of Participants With Relapse
Number of participants with relapse at one year. Relapse defined as recurrence of disease that required transplant.
Time frame: 1 year
Number of Participants With Clinically Relevant GVHD States Grade II-IV GVHD
Number of participants with clinically relevant GVHD states grade II-IV GVHD requiring systemic treatment. GVHD grades II-IV are defined as * Rash covering more than 50% of the body surface area, AND/OR * Total bilirubin \> 2 mg/dl AND/OR * Persistent nausea or vomiting, AND/OR * Diarrhea \> 500 ml/day AND/OR * Severe abdominal pain requiring treatment or blood present in the diarrhea
Time frame: 100 days
Number of Participants Achieving Overall Response
For patients who develop GVHD prior to day 100 post-HCT, the number of participants achieving overall response. The overall response rate = complete remission and partial remission (CR + PR) 28 days after initiation of systemic steroid treatment.
Time frame: Day 28
Number of Participants With Severe GI GVHD Stage 3 or 4
Number of participants with severe GI GVHD stage 3 or 4. GI GVHD stage 3 or 4 is defined as diarrhea \>1000 ml/day OR severe abdominal pain requiring treatment OR blood present in the diarrhea.
Time frame: By day 100 post-HCT
Number of Participants With Chronic GVHD Requiring Systemic Steroid Treatment
Number of participants with chronic GVHD requiring systemic steroid treatment. Chronic GVHD Requiring Systemic Steroid Treatment: defined as the development of symptoms of chronic GVHD according to NIH Consensus Criteria that require treatment with oral or intravenous corticosteroids.
Time frame: 1 year
Number of Participants With Serious Infections
Number of participants with serious infections (defined as grade 3 by the Blood and Marrow Transplant Clinical Trials Network). Serious Infection: Defined as bacterial, fungal, viral or parasitic infections that required oral or intravenous treatments such as antibiotics.
Time frame: 1 year
Subjects were recruited and enrolled between August 2018 and July 2019.
| Milestone | Alpha-1-antitrypsin (AAT) |
|---|---|
| Started | 30 |
| Completed | 21 |
| Not completed | 9 |
| Withdrew: Death | 8 |
| Withdrew: Withdrawal by subject | 1 |
Number of High Risk patients who develop steroid refractory GVHD by day 100 post Hematopoietic cell transplant (HCT) . Steroid refractory GVHD defined as patients who did not achieve Complete Response (CR) or Partial Response (PR) by day 28 of systemic steroid treatment OR if additional immunosuppression beyond steroids was given for treatment of GVHD prior to 28 days of steroid treatment. * CR: All evaluable organs (skin, liver, GI tract) stage 0. For a response to be scored as CR on day 28, the patient must be in CR on that day and have had no intervening additional GVHD therapy. * PR: An improvement in one or more organ involved with GVHD symptoms without worsening in others. For a response to be scored as PR on day 28, the patient must be in PR on that day and have had no intervening additional GVHD therapy.
| Participants | Alpha-1-antitrypsin (AAT) |
|---|---|
| Number of High Risk Patients Who Develop Steroid Refractory GVHD | 6 |
Overall survival - The number of that patients are still alive from the start of treatment at 6 months and 1 year
| Participants | Alpha-1-antitrypsin (AAT) |
|---|---|
| 6 months | 26 |
| 1 year | 22 |
Number of participants with NRM - deaths which could not be attributed to disease relapse or progression. Non-relapse mortality defined as death without prior relapse.
| Participants | Alpha-1-antitrypsin (AAT) |
|---|---|
| 6 months | 3 |
| 1 year | 6 |
Number of participants with relapse at one year. Relapse defined as recurrence of disease that required transplant.
| Participants | Alpha-1-antitrypsin (AAT) |
|---|---|
| Number of Participants With Relapse | 3 |
Number of participants with clinically relevant GVHD states grade II-IV GVHD requiring systemic treatment. GVHD grades II-IV are defined as * Rash covering more than 50% of the body surface area, AND/OR * Total bilirubin \> 2 mg/dl AND/OR * Persistent nausea or vomiting, AND/OR * Diarrhea \> 500 ml/day AND/OR * Severe abdominal pain requiring treatment or blood present in the diarrhea
| Participants | Alpha-1-antitrypsin (AAT) |
|---|---|
| Number of Participants With Clinically Relevant GVHD States Grade II-IV GVHD | 12 |
For patients who develop GVHD prior to day 100 post-HCT, the number of participants achieving overall response. The overall response rate = complete remission and partial remission (CR + PR) 28 days after initiation of systemic steroid treatment.
| Participants | Alpha-1-antitrypsin (AAT) |
|---|---|
| Number of Participants Achieving Overall Response | 10 |
Number of participants with severe GI GVHD stage 3 or 4. GI GVHD stage 3 or 4 is defined as diarrhea \>1000 ml/day OR severe abdominal pain requiring treatment OR blood present in the diarrhea.
| Participants | Number of Participants Requiring Steroid Treatment |
|---|---|
| Number of Participants With Severe GI GVHD Stage 3 or 4 | 4 |
Number of participants with chronic GVHD requiring systemic steroid treatment. Chronic GVHD Requiring Systemic Steroid Treatment: defined as the development of symptoms of chronic GVHD according to NIH Consensus Criteria that require treatment with oral or intravenous corticosteroids.
| Participants | Alpha-1-antitrypsin (AAT) |
|---|---|
| Number of Participants With Chronic GVHD Requiring Systemic Steroid Treatment | 8 |
Number of participants with serious infections (defined as grade 3 by the Blood and Marrow Transplant Clinical Trials Network). Serious Infection: Defined as bacterial, fungal, viral or parasitic infections that required oral or intravenous treatments such as antibiotics.
| Participants | Alpha-1-antitrypsin (AAT) |
|---|---|
| Number of Participants With Serious Infections | 2 |
Collected over up to 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpha-1-antitrypsin (AAT) | 8/30 (26.7%) | 14/30 (46.7%) | 9/30 (30%) |
| Event | Alpha-1-antitrypsin (AAT) |
|---|---|
| GVHDImmune system disorders | 4/30 |
| Bronchopulmonary hemorrhage (DAH)Respiratory, thoracic and mediastinal disorders | 2/30 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/30 |
| Pulmonary EdemaRespiratory, thoracic and mediastinal disorders | 2/30 |
| RelapseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/30 |
| Engraftment SyndromeGeneral disorders | 1/30 |
| HeadacheNervous system disorders | 1/30 |
| Line Infection: Gram negative Bacilli-CitrobacterInfections and infestations | 1/30 |
| PneumoniaInfections and infestations | 1/30 |
| Fungal Infection: Pneumocystis carinii pneumonia (PCP)Infections and infestations | 1/30 |
| Event | Alpha-1-antitrypsin (AAT) |
|---|---|
| Infusion ReactionInjury, poisoning and procedural complications | 5/30 |
| Atrial FibrillationCardiac disorders | 1/30 |
| Maculopapular rash with engraftment syndromeSkin and subcutaneous tissue disorders | 1/30 |
| Oral mucositisGastrointestinal disorders | 1/30 |
| Maculopapular RashSkin and subcutaneous tissue disorders | 1/30 |
| HypertensionCardiac disorders | 1/30 |
| KlebsiellaInfections and infestations | 1/30 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/30 |
| Generalized muscle weaknessGeneral disorders | 1/30 |
| Pulmonary EdemaRespiratory, thoracic and mediastinal disorders | 1/30 |
| Age, Continuous(years) | Alpha-1-antitrypsin (AAT) |
|---|---|
| Median | 51 (20 to 76) |
| Sex: Female, Male(Participants) | Alpha-1-antitrypsin (AAT) |
|---|---|
| Female | 11 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | Alpha-1-antitrypsin (AAT) |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Alpha-1-antitrypsin (AAT) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 28 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Diagnosis(Participants) | Alpha-1-antitrypsin (AAT) |
|---|---|
| Myelodysplastic syndrome | 13 |
| Acute myelogenous leukemia | 9 |
| Acute lymphoblastic leukemia | 5 |
| Nonmalignant disease | 2 |
| Non-Hodgkin's lymphoma | 1 |
| Donor(Participants) | Alpha-1-antitrypsin (AAT) |
|---|---|
| Matched related | 3 |
| Matched unrelated | 26 |
| Mismatched related | 0 |
| Mismatched unrelated | 1 |
| GVHD Prophylaxis(Participants) | Alpha-1-antitrypsin (AAT) |
|---|---|
| CNI/MTX - calcineurin inhibitor/methotrexate | 14 |
| CNI/MMF -Calcineurin inhibitors/mycophenolate mofetil | 0 |
| calcineurin inhibitor/sirolimus | 15 |
| Cyclophosphamide based | 0 |
| Other | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Aug 2020, 24 months.
Results were first posted in May 2021, 9 months after primary completion.
Of 85 non-industry phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 116. This study's 24 months is below that.
Counting every sponsor, half of 102 studies reached it within 51 months; a quarter within 29 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
John Levine